Posted on

Incyte Announces Positive Data from Phase 2b Trial of Ruxolitinib Cream in Patients with Atopic Dermatitis

Incyte Announces Positive Data from Phase 2b Trial of Ruxolitinib Cream in Patients with Atopic Dermatitis
WILMINGTON, Del.--(BUSINESS WIRE)--Sep. 13, 2018-- Incyte Corporation (Nasdaq:INCY)today announced positive results from its randomized, dose-ranging, vehicle- and active-controlled Phase 2b study evaluating ruxolitinib cream in patients with atopic ... .... ( read more )
Orginally Published At: Drugs – Clinical Trials